NorwayNorway

Norway

06.08.2004

Tustin/Oslo - US-based Peregrine Pharmaceuticals Inc. and Norwegian Affitech AS have recently achieved a research milestone involving the identification of fully human antibodies that specifically bind to the blood vessel growth factor Vascular Endothelial Growth Factor. As part of the collaboration, Affitech will further optimize the panel of antibodies. The antibodies are intended to be used in Peregrine's vascular targeting agent and anti-angiogenesis programmes.

NorwayNorway

08.03.2012

With a bold approach, including next-generation DNA sequencing (NGS) and state-of-the-art biobanking systems, Norway is pushing forward personalised cancer treatments in its national health care system. Clinical-quality genome...

NorwayNorway

06.03.2012

Bionor Pharma ASA’s development of an HIV vaccine is back on track. In mid-February, the Oslo-based company announced positive results from a Phase IIb study. When combined with antiretroviral treatment, the Vacc-4x vaccine...

NorwayNorway

19.01.2012

Oslo – The north lights up with financial flares. Norwegian cancer specialist Clavis Pharma ASA has raised €21m through a placement of new shares. The 2.8 million shares represent approximately 9.4% of the current stock in the...

NorwayNorway

11.01.2012

Bergen – BerGenBio A/S announced it has completed an €6.9m Series A financing round. The money will be spent in taking their lead compound BGB324 into clinical trials and to develop a companion diagnostic. The lead investors are...

NorwayNorway

13.12.2011

Reykjavik – Iceland’s deCODE Genetics, which Arch Venture Partners and Polaris Venture Partners lifted out of bankruptcy in January 2010, has been making a comeback of late. In mid-October, the genome analyser announced it had...

NorwayNorway

01.10.2011

Oslo/Leverkusen – Norwegian radiotherapy specialist Algeta ASA and German drugmaker Bayer have presented new data on their cancer drug alpharadin. The radium-223-chloride pharmaceutical showed an increased overall survival rate...

NorwayNorway

30.09.2011

Lysaker/Osaka - Pronova Biopharma SA is set on entering the Japanese market with its TAK-085 (omega-3-acid ethyl esters 90) for the treatment of hyperlipidemia. Pronova's partner Takeda Pharmaceutical Company Limited submitted a...

NorwayNorway

14.06.2011

Laskut/Berlin – Researchers from Finland’s Technical Research Center VTT and the Charité Hospital in the German capital have come a step closer to a personalised diagnostic test for cancer. Matej Orešic (VTT) and Carsten Denkert...

NorwayNorway

12.06.2011

Oslo – Norwegian cancer drug development company Clavis Pharma ASA will receive a grant from the Norwegian government for the development of a companion diagnostic in acute myeloid leuk­aemia (AML). The Research Council of Norway...

NorwayNorway

17.05.2011

Oslo – Clavis Pharma ASA has signed a licensing deal with US firm Translational Therapeutics, Inc., for the development and commercialization of CP-4033, a patented Lipid Vector Technology (LVT) derivative of ribavirin under...

Displaying results 1 to 10 out of 92

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/article/norway-4.html

Events

All Events

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • THERAMETRICS (CH)0.09 CHF12.50%
  • AB SCIENCE (F)11.21 EUR9.37%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.80 EUR268.4%
  • SANTHERA (CH)65.50 CHF81.9%
  • ADDEX (CH)4.01 CHF79.0%

FLOP

  • MERCK KGAA (D)65.21 EUR-48.8%
  • HYBRIGENICS (F)1.74 EUR-28.7%
  • PROSENSA (NL)9.65 USD-23.5%

TOP

  • SANTHERA (CH)65.50 CHF3175.0%
  • GW PHARMACEUTICALS (UK)412.50 GBP630.1%
  • PAION (D)2.74 EUR315.2%

FLOP

  • CYTOS (CH)0.28 CHF-91.8%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.45 EUR-69.7%

No liability assumed, Date: 28.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products